DE69517332T2 - Gefriergetrocknete ondansetron zubereitungen - Google Patents

Gefriergetrocknete ondansetron zubereitungen

Info

Publication number
DE69517332T2
DE69517332T2 DE69517332T DE69517332T DE69517332T2 DE 69517332 T2 DE69517332 T2 DE 69517332T2 DE 69517332 T DE69517332 T DE 69517332T DE 69517332 T DE69517332 T DE 69517332T DE 69517332 T2 DE69517332 T2 DE 69517332T2
Authority
DE
Germany
Prior art keywords
ondansetron
dosage form
free base
pharmaceutically acceptable
freeze
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69517332T
Other languages
German (de)
English (en)
Other versions
DE69517332D1 (de
Inventor
Keith Winterborn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Inc
SmithKline Beecham Corp
Original Assignee
Glaxo Wellcome Inc Canada
Glaxo Wellcome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10764757&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69517332(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Wellcome Inc Canada, Glaxo Wellcome Inc filed Critical Glaxo Wellcome Inc Canada
Application granted granted Critical
Publication of DE69517332D1 publication Critical patent/DE69517332D1/de
Publication of DE69517332T2 publication Critical patent/DE69517332T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Fertilizers (AREA)
DE69517332T 1994-11-22 1995-11-20 Gefriergetrocknete ondansetron zubereitungen Expired - Lifetime DE69517332T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9423511A GB9423511D0 (en) 1994-11-22 1994-11-22 Compositions
PCT/EP1995/004550 WO1996015785A1 (en) 1994-11-22 1995-11-20 Freeze-dried ondansetron compositions

Publications (2)

Publication Number Publication Date
DE69517332D1 DE69517332D1 (de) 2000-07-06
DE69517332T2 true DE69517332T2 (de) 2000-11-30

Family

ID=10764757

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69517332T Expired - Lifetime DE69517332T2 (de) 1994-11-22 1995-11-20 Gefriergetrocknete ondansetron zubereitungen

Country Status (30)

Country Link
US (2) US5955488A (https=)
EP (1) EP0793495B1 (https=)
JP (1) JP3001264B2 (https=)
KR (1) KR970706814A (https=)
CN (1) CN1080118C (https=)
AT (1) ATE193444T1 (https=)
AU (1) AU704160B2 (https=)
BE (1) BE1010250A3 (https=)
BR (1) BR9509808A (https=)
CY (1) CY2166B1 (https=)
CZ (1) CZ285250B6 (https=)
DE (1) DE69517332T2 (https=)
DK (1) DK0793495T3 (https=)
ES (1) ES2147309T3 (https=)
FI (1) FI119355B (https=)
FR (1) FR2727016B1 (https=)
GB (2) GB9423511D0 (https=)
GR (1) GR3033937T3 (https=)
HU (1) HU226891B1 (https=)
IL (1) IL116084A (https=)
IT (1) IT1282352B1 (https=)
MX (1) MX9703735A (https=)
NO (1) NO306893B1 (https=)
NZ (1) NZ296982A (https=)
PL (1) PL181179B1 (https=)
PT (1) PT793495E (https=)
RU (1) RU2159614C2 (https=)
TW (1) TW398976B (https=)
WO (1) WO1996015785A1 (https=)
ZA (1) ZA959821B (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
EP1952802A3 (en) * 1997-10-01 2009-06-17 Novadel Pharma Inc. Buccal, polar and non-polar spray or capsule
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
EP1246668B1 (en) * 1999-12-01 2005-11-30 Natco Pharma Limited An rapid acting freeze dired oral pharmaceutical composition for treating migraine
RU2162847C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона и его фармацевтически приемлемых солей
AU2002230935A1 (en) * 2000-10-30 2002-05-15 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
DK1499623T3 (da) * 2002-04-29 2007-10-08 Teva Gyogyszerg Ar Zartkoeruee Fremgangsmåde til fremstilling af 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-on
KR20040104677A (ko) * 2002-04-30 2004-12-10 비오갈 기오기스제르갸르 알티. 신규의 온단세트론 결정 형태, 그 제조 방법, 그 신규의결정 형태를 함유하는 약학 조성물 및 이들을 이용한구역질 치료 방법
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US7553853B2 (en) 2003-10-10 2009-06-30 Synthon Bv Solid-state montelukast
AR047459A1 (es) * 2004-01-27 2006-01-18 Synthon Bv Sales estables de 2-metil-4-(4-metil-1-piperazinil)-10h-tieno[2,3-b][1,5]benzodiazepina (olanzapina)
US20050272720A1 (en) * 2004-01-27 2005-12-08 Rolf Keltjens Process for making olanzapine Form I
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7501517B2 (en) * 2004-04-30 2009-03-10 Synthon Ip, Inc. Process for making montelukast and intermediates therefor
US7829716B2 (en) * 2004-04-30 2010-11-09 Synthon Pharmaceuticals, Inc. Process for making montelukast and intermediates therefor
DE602005016402D1 (de) * 2004-05-24 2009-10-15 Genvault Corp Stabile lagerung von protein und stabile lagerung von nukleinsäure in wiedergewinnbarer form
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
GB0516604D0 (en) * 2005-08-12 2005-09-21 Sandoz Ag Rapidly dispersing/disintegrating compositions
WO2007020080A1 (en) * 2005-08-17 2007-02-22 Synthon B.V. A process for making olanzapine form i
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
AR057909A1 (es) * 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
EP1996552A1 (en) * 2006-03-17 2008-12-03 Synthon B.V. Montelukast amantadine salt
US20070293479A1 (en) * 2006-05-18 2007-12-20 Osinga Niels J Olanzapine pharmaceutical composition
TWI343262B (en) * 2006-09-26 2011-06-11 Schering Corp Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist
US20080138409A1 (en) * 2006-09-29 2008-06-12 Osinga Niels J Olanzapine pharmaceutical composition
SI2124556T1 (sl) 2006-10-09 2015-01-30 Charleston Laboratories, Inc. Farmacevtske sestave
KR101441459B1 (ko) * 2006-10-24 2014-09-18 헬신 헬쓰케어 에스.에이. 안정성 및 생체이용률이 개선된 염산 팔로노세트론을 포함하는 연질 캡슐
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
RU2363463C1 (ru) * 2007-11-14 2009-08-10 Федеральное государственное унитарное предприятие Научно-производственный центр "Фармзащита" Федерального медико-биологического агентства Лекарственное средство
EP3090743A1 (en) 2008-01-09 2016-11-09 Charleston Laboratories, Inc. Pharmaceutical compositions for treating headache and eliminating nausea
EP2276739A1 (en) * 2008-04-25 2011-01-26 Synthon B.V. Process for making montelukast intermediates
DK2432467T3 (en) * 2009-05-20 2018-04-16 Inst Nat Sante Rech Med SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS FOR USE IN TREATMENT OF VESTIBULAR DAMAGE LESSONS
ES2432618T3 (es) * 2009-05-20 2013-12-04 Inserm (Institut National De La Santé Et De La Recherche Medicale) Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular
CA2767576C (en) 2009-07-08 2020-03-10 Charleston Laboratories Inc. Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
CA3055170A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
MX384045B (es) 2016-04-14 2025-03-14 Sensorion (+)-azasetrón para su uso en el tratamiento de trastornos del oído.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3275121D1 (en) * 1981-12-11 1987-02-19 Wyeth John & Brother Ltd Process for preparing solid shaped articles
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
US5288497A (en) * 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
GB8917556D0 (en) * 1989-08-01 1989-09-13 Glaxo Group Ltd Medicaments
US5188825A (en) * 1989-12-28 1993-02-23 Iles Martin C Freeze-dried dosage forms and methods for preparing the same
JPH0648960A (ja) * 1990-02-22 1994-02-22 Glaxo Group Ltd 医 薬
US5046618A (en) * 1990-11-19 1991-09-10 R. P. Scherer Corporation Child-resistant blister pack

Also Published As

Publication number Publication date
CZ285250B6 (cs) 1999-06-16
PL320295A1 (en) 1997-09-15
ES2147309T3 (es) 2000-09-01
ITRM950762A0 (https=) 1995-11-20
BR9509808A (pt) 1997-10-21
DK0793495T3 (da) 2000-10-09
IT1282352B1 (it) 1998-03-20
ATE193444T1 (de) 2000-06-15
NO972325L (no) 1997-05-22
FR2727016A1 (fr) 1996-05-24
GB9523667D0 (en) 1996-01-24
HK1009591A1 (en) 1999-06-04
IL116084A0 (en) 1996-01-31
KR970706814A (ko) 1997-12-01
ZA959821B (en) 1996-07-31
DE69517332D1 (de) 2000-07-06
JP3001264B2 (ja) 2000-01-24
NO972325D0 (no) 1997-05-21
US5955488A (en) 1999-09-21
HUT77886A (hu) 1998-09-28
JPH10508864A (ja) 1998-09-02
FI972167L (fi) 1997-05-21
NZ296982A (en) 1998-06-26
GR3033937T3 (en) 2000-11-30
FI972167A0 (fi) 1997-05-21
CZ154997A3 (en) 1997-10-15
CN1171741A (zh) 1998-01-28
ITRM950762A1 (it) 1997-05-20
GB2295318B (en) 1998-10-28
US6063802A (en) 2000-05-16
CN1080118C (zh) 2002-03-06
GB2295318A (en) 1996-05-29
CY2166B1 (en) 2002-08-23
GB9423511D0 (en) 1995-01-11
RU2159614C2 (ru) 2000-11-27
FI119355B (fi) 2008-10-31
IL116084A (en) 2000-01-31
MX9703735A (es) 1998-07-31
EP0793495A1 (en) 1997-09-10
WO1996015785A1 (en) 1996-05-30
AU4173996A (en) 1996-06-17
EP0793495B1 (en) 2000-05-31
AU704160B2 (en) 1999-04-15
PT793495E (pt) 2000-10-31
TW398976B (en) 2000-07-21
HU226891B1 (en) 2010-01-28
FR2727016B1 (fr) 1998-04-03
BE1010250A3 (fr) 1998-04-07
PL181179B1 (pl) 2001-06-29
NO306893B1 (no) 2000-01-10

Similar Documents

Publication Publication Date Title
DE69517332T2 (de) Gefriergetrocknete ondansetron zubereitungen
DE69518767T2 (de) Ondasetronhaltige oral anzuwendende arzneimittel
DE69502939T2 (de) Sublinguales oder bukkales arzneimittel
DE3931215C2 (de) Pharmazeutische Präparate auf der Grundlage von Ranitidin
DE60024491T2 (de) Schnell-wirkende, gefrier-trocknete, orale, pharmazeutische formulierung für die behandlung von migräne
DE3915347A1 (de) Harzadsorbat und verfahren zu seiner herstellung
DE68903605T2 (de) Kautablette.
DE602004009079T2 (de) Carbostyril-derivative zur beschleunigten speichelabsonderung
DD238920A5 (de) Verfahren zur herstellung einer verbesserten entzuendungshemmend wirkenden zusammensetzung
DE69415757T2 (de) Zusammensetzung zur Vorbeugung und Behandlung von Myopie
CA2205600C (en) Freeze-dried ondansetron compositions
MXPA97003734A (en) Oral compositions containing ondanset
DE3839883A1 (de) Pharmazeutisches praeparat

Legal Events

Date Code Title Description
8364 No opposition during term of opposition